Patent ID: 9732141
Date: 2017-08-15
CPC Classifications: A61K,A61P,C07K,C12N

Claim:
1. A method of treating a WT1-expressing malignancy in a patient, the method comprising introducing into the patient a T cell, which is modified to express a TCR molecule, the T cell receptor (TCR) molecule comprising an alpha chain portion and a beta chain portion wherein the alpha chain portion comprises three complementarity determining regions (CDRs): CDR1α: SSYSPS (SEQ ID NO: 2); CDR2α: YTSAATL (SEQ ID NO: 3); and CDR3α: VVSPFSGGGADGLT (SEQ ID NO: 4) or wherein the alpha chain portion comprises three CDRs: CDR1α: SSYSPS (SEQ ID NO: 2); CDR2α: YTSAATL (SEQ ID NO: 3); and CDR3α: comprising or consisting of SPFSGGGADGLT (SEQ ID NO: 5) and wherein the beta chain portion comprises three CDRs: CDR1β: DFQATT (SEQ ID NO: 6); CDR2β: SNEGSKA (SEQ ID NO: 7); and CDR3β: comprising SARDGGEG (SEQ ID NO: 8) or wherein the beta chain portion comprises three CDRs: CDR1β: DFQATT (SEQ ID NO: 6); CDR2β: SNEGSKA (SEQ ID NO: 7); and CDR3β: comprising or consisting of RDGGEGSETQY (SEQ ID NO: 9),